KPRX vs. ABVC, PPBT, TRAW, RDHL, NNVC, MIRA, EDSA, IMNN, PIRS, and AKTX
Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include ABVC BioPharma (ABVC), Purple Biotech (PPBT), Traws Pharma (TRAW), RedHill Biopharma (RDHL), NanoViricides (NNVC), MIRA Pharmaceuticals (MIRA), Edesa Biotech (EDSA), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
ABVC BioPharma (NASDAQ:ABVC) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
Kiora Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 1,315.57%. Given ABVC BioPharma's higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than ABVC BioPharma.
In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.
ABVC BioPharma has higher revenue and earnings than Kiora Pharmaceuticals.
Kiora Pharmaceuticals has a net margin of 0.00% compared to Kiora Pharmaceuticals' net margin of -6,919.08%. ABVC BioPharma's return on equity of -131.68% beat Kiora Pharmaceuticals' return on equity.
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ABVC BioPharma has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
Kiora Pharmaceuticals received 12 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
Summary
Kiora Pharmaceuticals beats ABVC BioPharma on 7 of the 11 factors compared between the two stocks.
Get Kiora Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiora Pharmaceuticals Competitors List
Related Companies and Tools
